Clinical Effectiveness Clinical studies have shown that semaglutide significantly reduces body weight and improves glycemic control when used consistently, along with diet and exercise
Journal of cellular and molecular medicine
References: Dimova, S., Hoet, P
The GLP-1 biosimilars market is gaining significant momentum, driven by the global surge in obesity and type 2 diabetes prevalence, escalating healthcare costs, and the growing need for accessible treatment options
Many users stack BPC-157 with GHK-Cu for synergistic repair effects, though larger human trials are still needed
However, researchers sometimes use BPC-157 alongside GLP-1 therapies to address gastrointestinal side effects, given its demonstrated gastroprotective properties